Cellectar Biosciences (CLRB) to Release Quarterly Earnings on Thursday

by · The Cerbat Gem

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Cellectar Biosciences to post earnings of ($1.91) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($3.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.60) by $0.21. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectar Biosciences Stock Down 1.2%

Shares of CLRB traded down $0.04 during trading hours on Friday, reaching $3.39. 70,827 shares of the company traded hands, compared to its average volume of 213,779. The business has a fifty day moving average price of $4.71 and a 200-day moving average price of $6.19. Cellectar Biosciences has a 12-month low of $3.17 and a 12-month high of $66.00. The stock has a market capitalization of $10.82 million, a P/E ratio of -0.17 and a beta of 0.56.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cellectar Biosciences stock. Bank of America Corp DE grew its position in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) by 25.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 206,783 shares of the biopharmaceutical company’s stock after purchasing an additional 41,704 shares during the quarter. Bank of America Corp DE owned approximately 0.45% of Cellectar Biosciences worth $62,000 as of its most recent SEC filing. 16.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CLRB. Roth Capital reissued a “buy” rating on shares of Cellectar Biosciences in a report on Thursday, August 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $375.00.

Read Our Latest Research Report on Cellectar Biosciences

Cellectar Biosciences Company Profile

(Get Free Report)

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

Featured Stories